Literature DB >> 15682321

Recent advances in embryonal tumours of the central nervous system.

Chitra Sarkar1, Prabal Deb, Mehar Chand Sharma.   

Abstract

INTRODUCTION: Embryonal tumours of the central nervous system (CNS) are the commonest malignant paediatric brain tumours. This group includes medulloblastomas, supratentorial primitive neuroectodermal tumours, atypical teratoid/rhabdoid tumours, ependymoblastomas, and medulloepitheliomas. Earlier, all these tumours were grouped under a broad category of primitive neuroectodermal tumours (PNETs). However, the current WHO classification (2000) separates them into individual types based on significant progress in the understanding of their distinctive clinical, pathological, molecular genetic, histogenetic, and behavioural characteristics. Furthermore, advances in histopathology and molecular genetics have shown great promise for refining risk assessment in these tumours, especially medulloblastomas, thus providing a more accurate basis for tailoring therapies to individual patients. Correlation of histological changes with genetic events has also led to a new model of medulloblastoma tumorigenesis. REVIEW: This review presents an updated comparative profile of these tumours, highlighting the clinical and biological relevance of the recent advances.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682321     DOI: 10.1007/s00381-004-1066-4

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  220 in total

1.  Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma.

Authors:  D A Reardon; J J Jenkins; J E Sublett; P C Burger; L K Kun
Journal:  Pediatr Neurosurg       Date:  2000-04       Impact factor: 1.162

Review 2.  Neurotrophins: roles in neuronal development and function.

Authors:  E J Huang; L F Reichardt
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

3.  Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta.

Authors:  M J Hart; R de los Santos; I N Albert; B Rubinfeld; P Polakis
Journal:  Curr Biol       Date:  1998-05-07       Impact factor: 10.834

4.  Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor.

Authors:  J A Biegel; B Fogelgren; L M Wainwright; J Y Zhou; H Bevan; L B Rorke
Journal:  Genes Chromosomes Cancer       Date:  2000-05       Impact factor: 5.006

5.  High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy.

Authors:  M C Frühwald; M S O'Dorisio; T Pietsch; J C Reubi
Journal:  Pediatr Res       Date:  1999-05       Impact factor: 3.756

6.  Nerve growth factor induces apoptosis in human medulloblastoma cell lines that express TrkA receptors.

Authors:  Y Muragaki; T T Chou; D R Kaplan; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  1997-01-15       Impact factor: 6.167

7.  Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins.

Authors:  V E Gould; D S Jansson; W M Molenaar; L B Rorke; J Q Trojanowski; V M Lee; R J Packer; W W Franke
Journal:  Lab Invest       Date:  1990-04       Impact factor: 5.662

8.  Altered neural cell fates and medulloblastoma in mouse patched mutants.

Authors:  L V Goodrich; L Milenković; K M Higgins; M P Scott
Journal:  Science       Date:  1997-08-22       Impact factor: 47.728

Review 9.  Medulloblastoma.

Authors:  C D Katsetos; P C Burger
Journal:  Semin Diagn Pathol       Date:  1994-05       Impact factor: 3.464

Review 10.  The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma.

Authors:  D G Evans; P A Farndon; L D Burnell; H R Gattamaneni; J M Birch
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

View more
  7 in total

Review 1.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

2.  XRCC4 suppresses medulloblastomas with recurrent translocations in p53-deficient mice.

Authors:  Catherine T Yan; Dhruv Kaushal; Michael Murphy; Yu Zhang; Abhishek Datta; Changzhong Chen; Brianna Monroe; Gustavo Mostoslavsky; Kristen Coakley; Yijie Gao; Kevin D Mills; Alex P Fazeli; Suprawee Tepsuporn; Giles Hall; Richard Mulligan; Edward Fox; Roderick Bronson; Umberto De Girolami; Charles Lee; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-02       Impact factor: 11.205

3.  Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome.

Authors:  Prasenjit Das; Tarun Puri; Vaishali Suri; M C Sharma; B S Sharma; Chitra Sarkar
Journal:  Childs Nerv Syst       Date:  2009-05-15       Impact factor: 1.475

4.  Efficacy of temozolomide for recurrent embryonal brain tumors in children.

Authors:  Chung-Hao Wang; Ting-Rong Hsu; Tai-Tong Wong; Kai-Ping Chang
Journal:  Childs Nerv Syst       Date:  2008-12-24       Impact factor: 1.475

5.  Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant.

Authors:  Saad Ali; Nancy M Joseph; Arie Perry; Ramon F Barajas; Soonmee Cha
Journal:  J Neurooncol       Date:  2014-06-04       Impact factor: 4.130

6.  Targeting inhibitors of apoptosis proteins suppresses medulloblastoma cell proliferation via G2/M phase arrest and attenuated neddylation of p21.

Authors:  Shu-Mei Chen; Tzu-Kang Lin; Yuan-Yun Tseng; Chiao-Hui Tu; Tai-Ngar Lui; Shiang-Fu Huang; Ling-Ling Hsieh; Ying-Ying Li
Journal:  Cancer Med       Date:  2018-07-09       Impact factor: 4.452

7.  Prenatal X-ray exposure and childhood brain tumours: a population-based case-control study on tumour subtypes.

Authors:  K Stålberg; B Haglund; O Axelsson; S Cnattingius; S Pfeifer; H Kieler
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.